Skip to main content

Head and Neck Cancer Resource Center

Featured

News
09/12/2022
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
05/18/2022
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
04/29/2022
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
04/26/2022
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
Quiz
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
News
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
Guideline Updates
03/24/2021
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
Quiz
02/01/2021
Journal of Clinical Pathways

Newsfeed

News
09/12/2022
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
05/18/2022
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
04/29/2022
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
04/26/2022
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
News
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
News
12/10/2020
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve...
12/10/2020
Journal of Clinical Pathways
News
02/05/2025
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
02/05/2025
This study identifies key barriers to care for patients with GI cancers, leading to the development of an equity-focused intervention to improve care delivery and address disparities in treatment.
This study identifies key barriers to care for patients with GI cancers, leading to the development of an equity-focused intervention to improve care delivery and address disparities in treatment.
This study identifies key...
02/05/2025
Journal of Clinical Pathways
News
02/03/2025
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways
News
02/03/2025
A study published in Blood Advances demonstrated that PIK3CA gains and PTEN losses in mantle cell lymphoma drive therapeutic resistance, metabolic reprogramming, and reduced dependence on B-cell receptor signaling, highlighting the need for...
A study published in Blood Advances demonstrated that PIK3CA gains and PTEN losses in mantle cell lymphoma drive therapeutic resistance, metabolic reprogramming, and reduced dependence on B-cell receptor signaling, highlighting the need for...
A study published in Blood...
02/03/2025
Journal of Clinical Pathways
News
01/22/2025
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer...
01/22/2025
Journal of Clinical Pathways
News
01/21/2025
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC...
01/21/2025
Journal of Clinical Pathways
News
01/15/2025
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint...
01/15/2025
Journal of Clinical Pathways
News
01/09/2025
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology

Interactive Features

Quiz
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
Quiz
02/01/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways